Canada Pension Plan Investment Board acquired a new position in shares of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) during the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm acquired 3,300 shares of the biopharmaceutical company’s stock, valued at approximately $178,000.

Several other large investors also recently modified their holdings of the stock. Sivik Global Healthcare LLC acquired a new stake in Portola Pharmaceuticals in the 2nd quarter valued at $1,685,000. State Street Corp increased its stake in Portola Pharmaceuticals by 5.3% in the 2nd quarter. State Street Corp now owns 2,085,838 shares of the biopharmaceutical company’s stock valued at $117,164,000 after buying an additional 105,207 shares during the last quarter. Russell Investments Group Ltd. acquired a new stake in Portola Pharmaceuticals in the 2nd quarter valued at $1,047,000. Numeric Investors LLC acquired a new stake in Portola Pharmaceuticals in the 2nd quarter valued at $753,000. Finally, Goldman Sachs Group Inc. increased its stake in Portola Pharmaceuticals by 17.2% in the 2nd quarter. Goldman Sachs Group Inc. now owns 688,092 shares of the biopharmaceutical company’s stock valued at $38,650,000 after buying an additional 101,046 shares during the last quarter. Institutional investors and hedge funds own 82.36% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this report on another domain, it was illegally copied and reposted in violation of US & international copyright & trademark law. The correct version of this report can be accessed at https://www.thecerbatgem.com/2017/11/23/canada-pension-plan-investment-board-invests-178000-in-portola-pharmaceuticals-inc-ptla.html.

Portola Pharmaceuticals, Inc. (NASDAQ PTLA) opened at $51.27 on Thursday. Portola Pharmaceuticals, Inc. has a 52 week low of $17.15 and a 52 week high of $67.10. The company has a debt-to-equity ratio of 0.24, a quick ratio of 8.31 and a current ratio of 8.31.

Portola Pharmaceuticals (NASDAQ:PTLA) last released its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported ($1.41) earnings per share for the quarter, topping the consensus estimate of ($1.49) by $0.08. The company had revenue of $3.83 million for the quarter, compared to analyst estimates of $4.71 million. Portola Pharmaceuticals had a negative net margin of 938.19% and a negative return on equity of 110.46%. Portola Pharmaceuticals’s revenue for the quarter was down 58.9% compared to the same quarter last year. During the same period in the previous year, the business earned ($1.64) EPS. research analysts expect that Portola Pharmaceuticals, Inc. will post -4.95 earnings per share for the current year.

PTLA has been the topic of several recent research reports. Morgan Stanley reiterated an “overweight” rating and issued a $81.00 price target (up from $75.00) on shares of Portola Pharmaceuticals in a research note on Friday, October 6th. Credit Suisse Group upgraded shares of Portola Pharmaceuticals from a “neutral” rating to an “outperform” rating and set a $70.00 price target on the stock in a research note on Wednesday, August 23rd. Oppenheimer Holdings, Inc. set a $80.00 price target on shares of Portola Pharmaceuticals and gave the company a “buy” rating in a research note on Friday, October 6th. BidaskClub upgraded shares of Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Friday, August 25th. Finally, Zacks Investment Research lowered shares of Portola Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Tuesday, August 8th. Four equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company’s stock. Portola Pharmaceuticals has an average rating of “Buy” and a consensus price target of $65.15.

Portola Pharmaceuticals Company Profile

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.

Want to see what other hedge funds are holding PTLA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Portola Pharmaceuticals, Inc. (NASDAQ:PTLA).

Institutional Ownership by Quarter for Portola Pharmaceuticals (NASDAQ:PTLA)

Receive News & Stock Ratings for Portola Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.